Literature DB >> 10559564

Posterior cortical atrophy variants of Alzheimer's disease.

J Aharon-Peretz1, O Israel, D Goldsher, A Peretz.   

Abstract

Posterior cortical atrophy (PCA) was first described by Benson in 1988 and, since then, has been regarded as a variant of Alzheimer's disease. We present 2 patients with symptoms suggestive of PCA and 2 patients with apraxia as the initial manifestation. Primary motor and sensory modalities were intact. Mild memory impairment was present early in the course of the disease and gradually worsened. Parieto-occipital atrophy was evident on brain MRI. HMPAO-SPECT demonstrated parieto-occipital hypoperfusion significantly different from the temporoparietal hypoperfusion usually described in senile dementia of the Alzheimer type. These findings suggest that HMPAO-SPECT can help in diagnosing atypical variants of Alzheimer's disease. We suggest that PCA represents two clinically related behavioral phenotypes: PCA with predominantly apraxia manifestations and PCA with predominantly visuospatial disturbances. Copyrightz1999S.KargerAG,Basel

Entities:  

Mesh:

Year:  1999        PMID: 10559564     DOI: 10.1159/000017194

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  17 in total

1.  Imaging correlates of posterior cortical atrophy.

Authors:  Jennifer L Whitwell; Clifford R Jack; Kejal Kantarci; Stephen D Weigand; Bradley F Boeve; David S Knopman; Daniel A Drubach; David F Tang-Wai; Ronald C Petersen; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2006-06-23       Impact factor: 4.673

2.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

3.  Posterior cortical atrophy: variant of Alzheimer's disease? A case series with PET findings.

Authors:  Klaus Schmidtke; Michael Hüll; Jochen Talazko
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

4.  Visual hallucinations in posterior cortical atrophy.

Authors:  Keith A Josephs; Jennifer L Whitwell; Bradley F Boeve; David S Knopman; David F Tang-Wai; Daniel A Drubach; Clifford R Jack; Ronald C Petersen
Journal:  Arch Neurol       Date:  2006-10

5.  Verbal fluency predicts mortality in Alzheimer disease.

Authors:  Stephanie Cosentino; Nikolaos Scarmeas; Steven M Albert; Yaakov Stern
Journal:  Cogn Behav Neurol       Date:  2006-09       Impact factor: 1.600

6.  Posterior cortical atrophy with unilateral occipito-temporal degeneration.

Authors:  Giacomo Koch; Alessandro Stefani; Marta Panella; Angela Giordano; Orazio Schillaci; Girolama A Marfia
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

7.  Latent atrophy factors related to phenotypical variants of posterior cortical atrophy.

Authors:  Colin Groot; B T Thomas Yeo; Jacob W Vogel; Xiuming Zhang; Nanbo Sun; Elizabeth C Mormino; Yolande A L Pijnenburg; Bruce L Miller; Howard J Rosen; Renaud La Joie; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici; Rik Ossenkoppele
Journal:  Neurology       Date:  2020-07-16       Impact factor: 9.910

8.  Objective metamemory testing captures awareness of deficit in Alzheimer's disease.

Authors:  Stephanie Cosentino; Janet Metcalfe; Brady Butterfield; Yaakov Stern
Journal:  Cortex       Date:  2007-10       Impact factor: 4.027

Review 9.  Posterior cortical atrophy.

Authors:  Sebastian J Crutch; Manja Lehmann; Jonathan M Schott; Gil D Rabinovici; Martin N Rossor; Nick C Fox
Journal:  Lancet Neurol       Date:  2012-02       Impact factor: 44.182

10.  Can patients without early, prominent visual deficits still be diagnosed of posterior cortical atrophy?

Authors:  A Suárez-González; S J Crutch; F Roldán Lora; E Franco-Macías; E Gil-Néciga
Journal:  J Neurol Sci       Date:  2016-05-13       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.